FDA clears first fully disposable duodenoscope, eliminating the potential for infections caused by ineffective reprocessing

The U.S. Food and Drug Administration today cleared for marketing in the U.S. the first fully disposable duodenoscope. The EXALT Model D Single-Use Duodenoscope is intended to provide visualization and access to the upper gastrointestinal (GI) tract to treat bile duct...

Webinar Addresses ‘Hot Topic’

The recent OR Today webinar “Human Factors and Quality Testing for Device Reprocessing” was sponsored by Healthmark and eligible for one (1) continuing education (CE) hour by the State of California Board of Registered Nursing. The 60-minute webinar featured Jahan...

Nihon Kohden Introduces First Subscription-Based Pricing for Patient Monitoring, Neurology Products

Nihon Kohden, a U.S. market leader in precision medical products and services, has launched subscription-based pricing models for its patient monitoring and neurology products, the first in the industry to take such a step. The pricing models help align costs with...

Nihon Kohden Launches Life Scope SVM-7200 Series

Nihon Kohden has announced the launch of its Life Scope SVM-7200 Series vital signs monitor, a monitor designed for outpatient facilities and beds that traditionally are not continuously monitored. The monitor allows health care practitioners to quickly and easily...

Five Studies Show Clinical Efficacy of 3M Skin and Nasal Antiseptic

In 2010, 3M Skin and Nasal Antiseptic was launched to help address the rising concern about surgical site infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. During the last three years, a growing body of evidence has proven the positive outcomes of utilizing this intervention as part of preoperative nasal preparation to reduce the risk of surgical site infection.

“At the time of launch, clinical studies had shown the antiseptic killed 99.5 percent of S. aureus in the nares in one hour and maintained that level for at least 12 hours, an important benefit for patients undergoing surgery who may be at risk for infection,” said DeAnn Hammer, Marketing Manager, 3M Infection Prevention Division. “We’ve now seen another handful of studies that continue to point to 3M Skin and Nasal Antiseptic as an important part of preoperative skin preparation to reduce the risk of SSI.”

Five distinct, third-party studies have confirmed 3M Skin and Nasal Antiseptic’s efficacy – both individually, and as part of a preoperative bundle of interventions focused on infection reduction.

Staphylococcus aureus is the leading cause of surgical site infections with approximately 80 percent of S. aureus infections caused by the patient’s own nasal flora. As the only product designed to work within the preoperative process to quickly and effectively reduce S. aureus colonization in the nares, healthcare providers can be confident their patients are entering surgery with a reduced risk of infection.



Submit a Comment

Your email address will not be published. Required fields are marked *